for people ages 4-17 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT ™) regimen in peanut-allergic children.

Official Title

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years


The primary objective is to assess the safety and tolerability of AR101 when used in a CODIT™ regimen for approximately 6 months in peanut-allergic children.


Peanut Allergy AR101 Characterized Peanut Allergen CPNA (Characterized Peanut Allergen) OIT (oral immunotherapy) Peanut-Allergic Children Desensitization ARC007 Characterized Oral Desensitization Immunotherapy (CODIT™) Peanut Hypersensitivity Peanut allergen formulation


For people ages 4-17

Key Inclusion Criteria:

  • Age 4 to 17 years, inclusive
  • History of physician-diagnosed peanut allergy
  • Positive SPT for peanut and elevated psIgE
  • Written informed consent from the subject's parent/guardian
  • Written assent from the subject as appropriate (per local regulatory requirements)
  • Use of effective birth control by sexually active female subjects of childbearing potential

Key Exclusion Criteria:

  • Subjects in whom the clinical diagnosis of peanut allergy is uncertain
  • History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension
  • History of severe or life-threatening episode of anaphylaxis or anaphylactic shock within 60 days of screening
  • History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD),symptoms of dysphagia or recurrent gastrointestinal symptoms of undiagnosed etiology
  • History of a mast cell disorder, including mastocytosis, urticaria pigmentosa, chronic idiopathic or chronic physical urticaria beyond simple dermatographism (e.g., cold urticaria, cholinergic urticaria), and hereditary or idiopathic angioedema
  • Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety


  • University of California, San Francisco
    San Francisco California 94158 United States
  • Allergy and Asthma Clinical Research, Inc.
    Walnut Creek California 94598 United States
  • Sean N. Parker Center for Allergy Research, LPCH at El Camino Hospital
    Mountain View California 94040 United States
  • Allergy & Asthma Associates of Santa Clara Valley Research Center
    San Jose California 95117 United States


in progress, not accepting new patients
Start Date
Completion Date
Aimmune Therapeutics, Inc.
Click to request more information about this study.
Phase 3
Study Type
Last Updated
July 3, 2018